[go: up one dir, main page]

IL136122A0 - Combination of active principles, in particular of tetrahydropyridines and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia - Google Patents

Combination of active principles, in particular of tetrahydropyridines and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia

Info

Publication number
IL136122A0
IL136122A0 IL13612298A IL13612298A IL136122A0 IL 136122 A0 IL136122 A0 IL 136122A0 IL 13612298 A IL13612298 A IL 13612298A IL 13612298 A IL13612298 A IL 13612298A IL 136122 A0 IL136122 A0 IL 136122A0
Authority
IL
Israel
Prior art keywords
dementia
tetrahydropyridines
combination
active principles
inhibiting agents
Prior art date
Application number
IL13612298A
Other languages
English (en)
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9714324A external-priority patent/FR2771006B1/fr
Priority claimed from FR9714322A external-priority patent/FR2771007B1/fr
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of IL136122A0 publication Critical patent/IL136122A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL13612298A 1997-11-14 1998-11-09 Combination of active principles, in particular of tetrahydropyridines and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia IL136122A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9714324A FR2771006B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR9714322A FR2771007B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
PCT/FR1998/002384 WO1999025363A1 (fr) 1997-11-14 1998-11-09 Association de principes actifs, notamment de tetrahydropyridines et d'agents inhibiteurs de l'acetylcholinesterase, pour le traitement de la demence senile du type alzheimer

Publications (1)

Publication Number Publication Date
IL136122A0 true IL136122A0 (en) 2001-05-20

Family

ID=26233932

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13612298A IL136122A0 (en) 1997-11-14 1998-11-09 Combination of active principles, in particular of tetrahydropyridines and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
IL136122A IL136122A (en) 1997-11-14 2000-05-14 Compounds of active ingredients, especially inhibitors of tetrahydropyridines and acetylcholinesterase carriers, for the treatment of dementia in adults, such as Alzheimer's dementia

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL136122A IL136122A (en) 1997-11-14 2000-05-14 Compounds of active ingredients, especially inhibitors of tetrahydropyridines and acetylcholinesterase carriers, for the treatment of dementia in adults, such as Alzheimer's dementia

Country Status (27)

Country Link
EP (1) EP1030671A1 (is)
JP (1) JP2001523642A (is)
KR (1) KR100599350B1 (is)
CN (1) CN1243540C (is)
AU (1) AU743228B2 (is)
BG (1) BG64819B1 (is)
BR (1) BR9814035A (is)
CA (1) CA2309966A1 (is)
CO (1) CO4980891A1 (is)
DZ (1) DZ2649A1 (is)
EA (1) EA003255B1 (is)
EE (1) EE04235B1 (is)
HU (1) HUP0100098A3 (is)
ID (1) ID24933A (is)
IL (2) IL136122A0 (is)
IS (1) IS5482A (is)
MY (1) MY120461A (is)
NO (1) NO20002450L (is)
NZ (1) NZ504420A (is)
OA (1) OA11464A (is)
PL (1) PL194597B1 (is)
SA (1) SA98190747B1 (is)
SK (1) SK286040B6 (is)
TR (1) TR200001262T2 (is)
TW (1) TW585766B (is)
UY (1) UY25247A1 (is)
WO (1) WO1999025363A1 (is)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0311780B8 (pt) * 2002-06-14 2021-05-25 Toyama Chemical Co Ltd composição farmacêutica para melhorar a função cerebral
DE60328198D1 (de) * 2002-08-07 2009-08-13 Novartis Ag Verfahren zur Vorhersage des Behandlungserfolgs mit Rivastigmine basierend auf einer Bestimmung des ApoE Genotyps eines Demenzkranken
CN1520818A (zh) * 2003-02-09 2004-08-18 山东绿叶天然药物研究开发有限公司 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
EP4023294A1 (en) 2014-01-31 2022-07-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating alzheimer's disease
KR102614814B1 (ko) 2017-05-15 2023-12-20 카그니션 테라퓨틱스, 인코퍼레이티드 신경변성 질환 치료용 조성물
WO2019182319A1 (ko) * 2018-03-20 2019-09-26 (주)인벤티지랩 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
KR102224918B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법
CN109265391B (zh) * 2018-11-13 2021-11-19 枣庄学院 联苯多取代1,2,5,6-四氢吡啶化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
CN1126546C (zh) * 1995-03-06 2003-11-05 英特纽隆制剂药有限公司 使用胞磷胆碱减少梗塞面积
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines

Also Published As

Publication number Publication date
WO1999025363A1 (fr) 1999-05-27
JP2001523642A (ja) 2001-11-27
TW585766B (en) 2004-05-01
EE200000290A (et) 2001-06-15
EA200000412A1 (ru) 2000-12-25
CA2309966A1 (en) 1999-05-27
BG104428A (en) 2001-08-31
AU743228B2 (en) 2002-01-24
TR200001262T2 (tr) 2001-01-22
DZ2649A1 (fr) 2004-12-28
AU1160999A (en) 1999-06-07
NZ504420A (en) 2003-08-29
CN1243540C (zh) 2006-03-01
SK286040B6 (sk) 2008-01-07
PL340500A1 (en) 2001-02-12
KR100599350B1 (ko) 2006-07-12
MY120461A (en) 2005-10-31
HUP0100098A2 (hu) 2001-07-30
IL136122A (en) 2006-07-05
SK7112000A3 (en) 2000-10-09
IS5482A (is) 2000-05-09
EP1030671A1 (fr) 2000-08-30
OA11464A (en) 2003-11-18
HUP0100098A3 (en) 2001-12-28
CN1285742A (zh) 2001-02-28
BR9814035A (pt) 2000-09-26
BG64819B1 (bg) 2006-05-31
EE04235B1 (et) 2004-02-16
PL194597B1 (pl) 2007-06-29
UY25247A1 (es) 2001-05-31
KR20010032099A (ko) 2001-04-16
CO4980891A1 (es) 2000-11-27
NO20002450L (no) 2000-07-14
SA98190747B1 (ar) 2006-11-04
NO20002450D0 (no) 2000-05-11
EA003255B1 (ru) 2003-02-27
ID24933A (id) 2000-08-31

Similar Documents

Publication Publication Date Title
HUP0103920A3 (en) Methods and compositions for the prevention and treatment of anemia
IL125236A0 (en) Disinfecting compositions and processes for disinfecting surfaces
AU2001239052A1 (en) Compositions for prevention and treatment of dementia
HUP0104410A3 (en) A composition for the prevention and/or treatment of atherosclerosis
HUP9901883A3 (en) Disinfecting composition and process for disinfecting surfaces
IL136122A0 (en) Combination of active principles, in particular of tetrahydropyridines and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
IL125307A0 (en) Disinfecting compositions and processes for disinfecting surfaces
HUP0001629A3 (en) Method for treating plants and copperchelate containing compositions for it
HUP9903720A3 (en) Process and agents for controlling harmful fungi
HUP9700598A3 (en) Process for producing pharmaceutical composition useful for profilacting and treating pancreatitis
IL131085A0 (en) The use of levobupivacaine or ropivacaine in treating migraine
HU9800396D0 (en) Pharmaceutical composition for treating dementia
GB9611614D0 (en) Process for inhibiting the effect of flourescent whitening agents
HUP0002709A3 (en) Process for the reduction of 1-substituted -3-hydroxymethyl-4- (4-fluorophenyl)tetrahydropyridines
HK1028354A (en) Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
ZA962636B (en) Compositions and process for treating hemangioma
EP1246952A4 (en) COMPOSITION AND METHOD FOR TREATING METALS
IL128095A0 (en) Formulation for the treatment and/or prophylaxis of dementia
EP0708638A4 (en) METHODS AND COMPOSITIONS FOR TREATING DEPRESSION AND OTHER PSYCHIATRIC DISEASES
ZA989955B (en) Combination of active ingredients for the treatment of senile dementia of the alzheimer type
HK1022648A (zh) 治疗偏头痛的药物
HUP0100613A3 (en) Methods and compositions for stabilizing acetylcholine compositions
EP1173159A4 (en) COMPOSITION AND METHOD FOR TREATING COLIC
ZA974390B (en) Carboxamide derivatives of pyrrolidine piperidine and hexahydroazepine for the treatment of thrombosis disorders.
HU9602459D0 (en) Process and composition for preventing discolouration of maleicanhydride

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees